Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy [Yahoo! Finance]
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.